SCHEMBL1662696

SCHEMBL1662696

COC(=O)c1nn2ccccc2c1C(=O)OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
MIF P14174 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
PDE5A O76074 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
TSHR P16473 1/20 0.48
PDE4A P27815 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA1 P30542 1/20 0.48
BLM P54132 1/20 0.48
PDE4B Q07343 1/20 0.48
PDE4C Q08493 1/20 0.48
PDE4D Q08499 1/20 0.48
PDE3B Q13370 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4175500 0.91 ELANE (0.48) ALDH1A1MEN1KMT2AMIFCYP3A4
SCHEMBL15897069 0.84 MEN1 (0.48) ALDH1A1MEN1KMT2AMIFCYP3A4
SCHEMBL15897073 0.83 EGFR (0.47) ALDH1A1MEN1KMT2AMIFCYP3A4
SCHEMBL3694469 0.81 ALDH1A1 (0.47) ALDH1A1MEN1KMT2ACYP3A4CYP2C9
SCHEMBL38666633 0.81 EGFR (0.48) ALDH1A1MEN1KMT2AMIFCYP3A4
SCHEMBL2437722 0.79 EGFR (0.46) ALDH1A1MEN1KMT2AMIFCYP3A4
SCHEMBL30230692 0.78 ELANE (0.44) ALDH1A1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL22148204 0.78 ELANE (0.43) ALDH1A1MEN1KMT2ACYP3A4TSHR
SCHEMBL23961102 0.78 EPHB3 (0.54) ALDH1A1CYP1A2ELANEPLAUF2
SCHEMBL23387905 0.77 ELANE (0.41) ALDH1A1MEN1KMT2AMIFCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119431394-A Pyridazinone derivatives and medical application thereof 杭州百新生物医药科技有限公司 2025-02-14 CN disclosed
US-11993729-B2 Chemical mechanical polishing composition BASF SE (DE) 2024-05-28 US disclosed
EP-4061815-B1 PYRIMIDONE DERIVATIVES CONTAINING TWO FUSED BICYCLIC RINGS BASF SE (DE) 2024-03-20 EP disclosed
EP-3714012-B1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2023-01-11 EP disclosed
US-20220411428-A1 Pyrimidone Derivatives Containing Two Fused Bicyclic Rings BASF SE (DE) 2022-12-29 US disclosed
EP-4061815-A1 PYRIMIDONE DERIVATIVES CONTAINING TWO FUSED BICYCLIC RINGS BASF SE (DE) 2022-09-28 EP disclosed
US-11420944-B2 Voltage-dependent t-type calcium channel blocker NIPPON CHEMIPHAR CO., LTD. (JP) 2022-08-23 US disclosed
CN-114728977-A Pyrimidone derivatives containing two fused bicyclic rings 巴斯夫欧洲公司 2022-07-08 CN disclosed
WO-2021099240-A1 PYRIMIDONE DERIVATIVES CONTAINING TWO FUSED BICYCLIC RINGS BASF SE (DE) 2021-05-27 WO disclosed
US-20210102093-A1 USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES BASF SE (DE) 2021-04-08 US disclosed
WO-2019101555-A1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2019-05-31 WO disclosed
US-20190077767-A1 VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER NIPPON CHEMIPHAR CO., LTD. (JP) 2019-03-14 US disclosed
EP-3404021-A1 VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2018-11-21 EP disclosed
EP-3334794-A1 USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES BASF SE (DE) 2018-06-20 EP disclosed
WO-2017025536-A1 USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES BASF SE (DE) 2017-02-16 WO disclosed
WO-2015066371-A1 SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS FORUM PHARMACEUTICALS, INC. (US) 2015-05-07 WO disclosed
WO-2011050284-A1 PYRAZOLYLPYRIDINE ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2011-04-28 WO disclosed
EP-2090576-A1 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators Merz Pharma GmbH & Co.KGaA (DE) 2009-08-19 EP disclosed
WO-2009095253-A1 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2009-08-06 WO disclosed
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof SCHWARZ PHARMA AG (DE) 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411428-A1 Pyrimidone Derivatives Containing Two Fused Bicyclic Rings DDT, DHFR, PFAS ALDH1A1 526/4885MEN1 3102/4885KMT2A 3514/4885
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof GRIN2A, GRIN2C, GRIN1 ALDH1A1 459/4885MEN1 1227/4885KMT2A 455/4885
US-11420944-B2 Voltage-dependent t-type calcium channel blocker CACNA1I, CACNA1G, CACNA1E ALDH1A1 3247/4885MEN1 2133/4885KMT2A 1735/4885
US-20190077767-A1 VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER CACNA1I, CACNA1G, CACNA1E ALDH1A1 3220/4885MEN1 1995/4885KMT2A 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.